Parliament Workbench
Data: Motions & questions to 19 Nov 2026 · Votes to 12 Nov 2026

Members' Business Motion · S2M-02602 · Session 2

Treatment of Alzheimer's Disease

Lodged by John Swinburne SSCUP Lodged 16 Mar 2005 19 supporters

The motion

That the Parliament notes with concern the preliminary recommendations of the National Institute for Clinical Excellence (NICE) which, while recognising the effectiveness of three dementia drugs, donepezil, rivastigmine and galantamine, to many sufferers, recommends withdrawing these drugs on the grounds of cost to the NHS in England and Wales; endorses the call by Alzheimer Scotland that all patients with Alzheimer’s disease who are considered suitable by their doctors for these treatments should receive them until it can be shown that either they are not or are no longer benefiting, and considers that the Scottish Executive should ensure that the NICE recommendations are not adopted by NHS Scotland to avoid a disastrous decision for the 62,000 sufferers of dementia in Scotland and their families.

Signatures by party

19 MSPs besides the lodger · 19 from other parties
SNP 9SSP 4Con 3Ind 2LD 1

Party on the day each MSP signed. Signing a motion is voluntary and not whipped. Who signs whose motions

Vote

No recorded vote on this motion. Most motions are never debated, and many that are debated are agreed without a division. Vote records are published from 2011.

Supporters

19 MSPs

SNP 9 SSP 4 Con 3 Ind 2 LD 1

Show all 19 supporters by party

SNP 9

SSP 4

Con 3

Ind 2

LD 1

Party shown is each supporter’s party when the motion was published.

In the Official Report

No contribution in the Official Report cites S2M-02602 by reference.